1. Controversies in multiple myeloma: Evidence-based update
Inhye E. Ahn, Sham Mailankody 
Seminars in Oncology 
Volume 43, Issue 6, Pages (December 2016)
DOI: /j.seminoncol
Copyright © 2016 Elsevier. Terms and Conditions

2. Fig. 1
Probability of progression to active multiple myeloma or primary amyloidosis in patients with smoldering multiple myeloma or monoclonal gammopathy of undetermined significance. Adapted from Kyle et al [1].
Seminars in Oncology  , DOI: ( /j.seminoncol )
Copyright © 2016 Elsevier. Terms and Conditions

3. Fig. 2
Discrepancy between Mayo clinic and Spanish risk stratification models in smoldering multiple myeloma. Adapted with permission [6].
Seminars in Oncology  , DOI: ( /j.seminoncol )
Copyright © 2016 Elsevier. Terms and Conditions

4. Fig. 3
Comparison of upfront high-dose therpy and single autologous stem cell transplant (HDT) and nonmyeloablative standard-dose therapy (SDT). (A) Forest plot of overall survival comparing benefit of HDT and SDT. (B) Assessment of potential harm with upfront HDT. The table presents the anticipated transplant-related mortality (TRM) with upfront HDT (based on threefold increased odds of death with HDT versus SDT), for a range of possible TRM rates in the SDT arm. Based on these estimates, the number of patients that need to be enrolled to the HDT arm to have oneexcess HDT toxicity-related death (v those in the SDT arm) is also indicated, as is the number of such excess deaths anticipated per 1,000 patients enrolled to upfront HDT. Adapted with permission [32].
Seminars in Oncology  , DOI: ( /j.seminoncol )
Copyright © 2016 Elsevier. Terms and Conditions